PATENT CLAIM ANALYSIS

Application Number: 16100105
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-07
Patent Classification: ["514", "004800"]

Abstract:
The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Claim (Index 4):
The method of  claim 1 , wherein the metabolic syndrome is characterized by diabetes, impaired glucose tolerance, impaired fasting glucose, or insulin resistance plus two or more of the following abnormalities:\n (a) high blood pressure: \u2265160/90 mm Hg; (b) hyperlipidemia: triglyceride concentration \u2265150 mg/dl (1.695 mmol/l) and/or HDL cholesterol <35 mg/dl (0.9 mmol/l) in men and <39 mg/dl (1.0 mmol/l) in women; (c) central obesity: waist-to-hip ratio of >0.90 in men or >0.85 in women or BMI >30 kg/m 2 ; and (d) microalbuminuria: urinary albumin excretion rate \u226520 \u03bcg/min or an albumin to creatinine ratio \u226520 mg/g.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 96.0
- Lexical Diversity: 1.2963
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13897070', '14671538', '15401527', '12367267', '12392565']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7884884507221372
- 35 USC 102 Novelty (BERT): 0.5318342735001345
- Combined Prediction Score: 0.762823032999937
- Mean Citation Score: 333.911284
- Max Citation Score: 342.51965
- Similarity Product: 216.0633377225965

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test